Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

November 14, 2024

Study Completion Date

November 14, 2024

Conditions
Cardiomyopathies, Primary
Interventions
DRUG

(18F)Flutemetamol

18F-Flutemetamol binds to β-amyloid plaques and the F-18 isotope produces a positron signal that is detected by a PET scanner. Multiple recent studies have shown that thioflavin-analogue tracers such as 18F-flutemetamol may be able to fulfill the unmet need of elucidating the presence of amyloid deposition in the heart. Because it binds to the beta-pleated motif of the amyloid fibril due to their similarity to the thioflavin structure, 18F-Flutemetamol could potentially be used to image cardiac amyloidosis (CA)

Trial Locations (1)

06520

Yale University, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Yale University

OTHER

NCT05374564 - Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy | Biotech Hunter | Biotech Hunter